Tadalafil API Export to Brazil: Understanding CADIFA and ANVISA Timelines
Brazil is one of the largest and fastest-growing pharmaceutical markets in Latin America, which makes it a natural target for any serious API supplier. But a tadalafil API export to Brazil isn’t as simple as shipping a WHO-GMP certificate and a Certificate of Analysis. Brazil’s regulator, ANVISA (Agência Nacional de Vigilância Sanitária), runs one of the most document-heavy API approval systems in the region and if you don’t understand the CADIFA process going in, you can lose months on preventable delays.
This guide breaks down exactly what Brazilian formulators and importers need from their API supplier, how the CADIFA system works, and what timeline to actually plan for.
Why Brazil Matters for API Exporters
Brazil’s pharmaceutical market has grown consistently over the past several years, and generic and branded-generic manufacturers there are constantly sourcing PDE5-inhibitor APIs like tadalafil for both domestic formulation and re-export across Mercosur. For Indian API manufacturers, Brazil represents a high-volume, long-term relationship market — but only for suppliers who can navigate ANVISA’s documentation requirements correctly the first time.
ANVISA: Brazil’s Pharmaceutical Regulator
ANVISA is Brazil’s national health surveillance agency, operating under the Ministry of Health. Every API used in a locally registered drug product must be backed by ANVISA-recognized documentation before the finished product can even begin its own registration process. This is where CADIFA comes in.
What Is CADIFA?
CADIFA (Carta de Adequabilidade do Dossiê de Insumo Farmacêutico Ativo) is essentially ANVISA’s official letter of acceptance for an API’s dossier or Drug Master File. Think of it as Brazil’s equivalent of a CEP (Certificate of Suitability) — it confirms that ANVISA has reviewed and accepted the quality and GMP documentation behind a specific API, from a specific manufacturing site.
A few things every buyer and exporter should know about CADIFA:
- It was introduced in 2020, with a three-year grace period that ended in August 2023 — CADIFA is now a hard requirement, not optional documentation.
- Only the DMF holder can formally request the CADIFA from ANVISA.
- A foreign API manufacturer can complete the CADIFA submission independently — a Brazilian regulatory agent is not mandatory for this specific filing, though most exporters use one to avoid translation and portal issues.
- Once granted, a single CADIFA can support multiple downstream drug product registrations without requiring re-evaluation each time. This is a major efficiency advantage if you’re supplying multiple formulators in Brazil.
Realistic ANVISA Timelines for Tadalafil API
This is the part most first-time exporters underestimate. For a single-API medicinal product, ANVISA’s typical review window runs 15 to 18 months. If the finished product is a fixed-dose combination, expect closer to 24 months.
That timeline covers the full product registration process, not just the API dossier acceptance — but since CADIFA sits at the front of that chain, delays here cascade through everything downstream. A rejected or incomplete DIFA (Dossiê de Insumo Farmacêutico Ativo) submission can add several additional months before the clock even properly starts.
Documentation Checklist for Tadalafil API Export to Brazil
Before approaching a Brazilian buyer or agent, make sure your documentation package includes:
- Valid GMP certificate from the country of origin — certificates in English or Spanish are accepted without requiring a sworn translation.
- Site Master File (SMF) or Plant Master File covering the manufacturing facility.
- Complete DIFA/DMF structured for ANVISA’s eCTD-based submission format.
- Stability data aligned to Brazil’s climatic zone requirements (Zone IVA/IVB — hot and humid conditions), which are stricter than many other export markets.
- Certificate of Analysis (CoA) matching the exact batch and specification data referenced in the dossier.
ANVISA can also schedule a GMP inspection of the manufacturing site as part of the review, with certificate issuance typically taking 45–60 days after a successful inspection.
Common Mistakes That Delay Brazilian Registration
- Submitting a DIFA that doesn’t match the finished product’s registration dossier data exactly (names, specifications, batch references).
- Underestimating Brazil’s climatic zone stability requirements, which are more demanding than temperate-market submissions.
- Assuming CADIFA approval guarantees a fast finished-product registration — it removes one bottleneck, not all of them.
- Not confirming who legally holds DMF rights before starting the CADIFA request, since only the DMF holder can file it.
Why WHO-GMP Certified Sourcing Matters Here
Given how document-intensive Brazil’s approval process is, sourcing tadalafil API from a WHO-GMP certified, export-experienced manufacturer materially reduces the risk of rejected submissions. Chemox Pharma’s Dahej, Gujarat facility maintains full WHO-GMP documentation and export experience across 20+ countries, with dossier support built for exactly this kind of scrutiny-heavy market.
Meet Us at Pharmaconex Egypt 2026
If you’re a Brazilian or Latin American formulator sourcing tadalafil API and want to discuss documentation, DMF access, and bulk pricing in person, Chemox Pharma will be at Pharmaconex Egypt 2026 — Stand H3.K61, Cairo, 1–3 September 2026.
FAQs
Q: Is CADIFA mandatory for all tadalafil API imports into Brazil? Yes. Since the August 2023 grace period ended, any API used in a Brazilian drug product registration requires a valid CADIFA.
Q: Who can apply for a CADIFA — the API manufacturer or the importer? Only the DMF holder can formally request it, though the submission itself can be prepared and filed by the foreign manufacturer directly.
Q: How long does a tadalafil API export to Brazil realistically take from first contact to market? Budget 15–18 months for a standard single-API product registration, and closer to 24 months for fixed-dose combinations — CADIFA acceptance is only the first stage of that timeline.
Q: Does the GMP certificate need to be translated into Portuguese? No — GMP certificates issued in English or Spanish are accepted by ANVISA without a sworn translation requirement.
